NEWPORT NEWS, Va. — January 10, 2024 — ivWatch, LLC, the IV safety company, today announced its participation in Arab Health 2024, where it will exhibit its patented biosensor technology which is being increasingly adopted in the Middle East. The company has seen an increased demand for its products in the region due to growing awareness of IV infiltration and extravasation injuries and as healthcare decision makers place emphasis on preventing them. ivWatch is located at booth H2.G57.
ivWatch is the inventor and manufacturer of the only FDA-cleared and CE Marked continuous IV site monitoring technology to detect extravasations. The company’s robust patent portfolio has expanded to 71 patents around the world protecting its core technologies and reinforcing its commitment to current and future innovations. The medical device technologies work as a monitoring system to notify clinicians in real time of an IV infiltration or extravasation, which helps reduce patient harm and improve outcomes in IV therapy.
The ivWatch system has been clinically tested in laboratory and real-world settings, most recently in two new third-party studies in Europe, now surpassing over 30 clinical studies. In a new study conducted by Gemelli University Polyclinic in Rome published in The Journal of Vascular Access (JVA), the continuous IV monitoring system was deployed to identify the leakage of intravenous infused fluids in infants receiving infusions by the peripheral route. The study found that continuous infusion site monitoring using the ivWatch system detected an 80% infiltration rate. This infiltration rate is an unfortunate normal in neonatal units, significantly higher than other hospital unit’s infiltration rates. The study found an overall sensitivity of 88.9% in detecting infiltration before the clinician, where the clinician is considered the gold standard. On average, infiltration events were detected six hours prior to a clinical diagnosis.
A recent study published in The Journal of Vascular Access (JVA) examines the monitoring of infiltrations and extravasations in a 24-bed neonatal intensive care unit (NICU) at Wilhelmina Children’s Hospital, part of the University Medical Centre of Utrecht in the Netherlands. It found that continuous infusion site monitoring using the ivWatch system detects PIVIE events earlier rather than relying on intermittent visual observation alone, and that detection occurred in 100% of leakage events prior to a clinician detecting such an event. During the study with ivWatch technology, 11 infiltrations were detected in 21 monitored PIVCs, which corresponds to a 52.4% infiltration incidence rate.
Arab Health provides a platform to address and outline global healthcare challenges while providing attendees with opportunities to network with industry leaders from around the world and enables companies to showcase progress and achievements in the sector. This year’s focus at Arab Health “will be channeling into the future of healthcare with global innovations never seen before.”
To schedule an appointment to speak with ivWatch executives at the event, please book your appointment here. To learn more about the ivWatch patient monitoring system for IV infiltrations and extravasations visit: https://www.ivwatch.com/tech-overview/.
About ivWatch, LLC
ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative IV monitoring solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch, Facebook @ivWatchLLC, Instagram @ivWatchLLC and LinkedIn @ivWatch-LLC, or visit www.ivWatch.com.